^
Association details:
Biomarker:TP53 mutation + KRAS mutation
Cancer:Lung Adenocarcinoma
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.

Excerpt:
Patients (pts) with metastatic KRAS-mutant LUAC who received at least one cycle of PD-1/PD-L1 therapy...in STK11/LKB1(KL) or TP53 (KP) define subgroups...Best overall response differed significantly in the KL (PR: 9.1%, SD: 15.9%, PD: 75%) and KP (PR: 33.3%, SD: 20%, PD: 46.7%) sub-groups (P = 0.005, Fisher’s exact test).
DOI:
10.1200/JCO.2017.35.15_suppl.9016